Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pacific Edge Limited ( (PFGTF) ) has shared an announcement.
Pacific Edge has requested a trading halt on its securities on the ASX and NZX from before market open on 20 February 2026, pending an announcement linked to a key U.S. Medicare policy meeting. Trading is expected to remain halted until either normal trading resumes on 24 February or the company releases its update to the market.
The halt coincides with a public Contractor Advisory Committee meeting called by Novitas, the company’s Medicare Administrative Contractor, to review evidence for urine-based biomarkers in patients with microhematuria. Because the discussion may signal whether Novitas will move toward a local coverage determination that could support or continue to deny Medicare reimbursement for Cxbladder, Pacific Edge says it needs time to assess the outcome and provide context for investors before trading resumes.
More about Pacific Edge Limited
Pacific Edge Limited is a diagnostics company listed on both the ASX and NZX, focused on urine-based biomarker tests for urological conditions such as microhematuria. Its flagship product, Cxbladder, targets the U.S. healthcare market through Medicare reimbursement, making U.S. medical policy developments critical to its business outlook.
See more insights into PFGTF stock on TipRanks’ Stock Analysis page.